Latest Amylin Pharmaceuticals Inc. Stories
LA JOLLA, Calif., Jan. 31, 2013 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today the appointment of Mark G. Foletta to its Board of Directors and Audit Committee, effective immediately. "We are very pleased to have Mark join our Board," said John Maraganore, Ph.D., Chairman of the Board of Directors of Regulus and CEO of Alnylam...
SAN DIEGO, Jan. 4, 2013 /PRNewswire/ -- BioMed Realty Trust, Inc. (NYSE: BMR) today announced the appointment of Daniel M. Bradbury to its board of directors, increasing the board to eight members. "We are pleased to welcome Dan to our board," said Alan D. Gold, Chairman and Chief Executive Officer of BioMed Realty. "Dan brings his extensive knowledge of the life science industry, as well as proven experience as a successful and dynamic leader, which we believe will contribute...
OSAKA, Japan and DEERFIELD, Ill., Dec. 24, 2012 /PRNewswire/ -- Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that it has mutually terminated its worldwide agreement with Amylin Pharmaceuticals, Inc., originally signed in October 2009, to co-develop and commercialize compounds for obesity. The companies announced in August 2011 their decision to discontinue the development of pramlintide/metreleptin, an investigational combination therapy for the treatment of...
CHICAGO, July 12, 2012 /PRNewswire/ -- Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include WellPoint Inc. (NYSE:WLP), AMERIGROUP Corporation (NYSE:AGP), Bristol-Myers Squibb Company (NYSE:BMY), Amylin Pharmaceuticals, Inc. (Nasdaq:AMLN), and Eli Lilly & Company (NYSE:LLY). (Logo:...
DALLAS, July 9, 2012 /PRNewswire/ -- Securities lawyers at Goldfarb LLP are investigating alleged violations of shareholder protection laws by officers and directors of Amylin Pharmaceuticals, Inc. (NASDAQ: AMLN) in connection with a buyout for $31.00 per share to Bristol-Myers Squibb. Concerned AMLN investors are encouraged to contact attorney Hamilton Lindley at 877-583-2855 or hlindley@goldfarbllp.com about their rights and remedies. "Amylin's recently approved diabetes drug,...
BALA CYNWYD, Pa., July 3, 2012 /PRNewswire/ -- Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Amylin Pharmaceuticals, Inc. ("Amylin" or the "Company") (Nasdaq - AMLN) relating to the proposed acquisition by Bristol-Myers Squibb Company ("Bristol-Myers"). Under the terms of the transaction, Amylin shareholders will receive only $31.00 in cash for each of Amylin stock they own. The investigation concerns...
VANCOUVER, British Columbia, July 3, 2012 /PRNewswire-Asia/ -- Insiderslab.com has issued insider trading reports and Equity Research for the following companies: Bank of America (NYSE:BAC), Amylin Pharmaceuticals (NASDAQ:AMLN), Bristol Myers Squibb (NYSE:BMY), Constellation Brands (NYSE:STZ), US Airways Group (NYSE:LCC), and Alpha Natural Resources (NYSE:ANR). (Logo: http://photos.prnewswire.com/prnh/20100419/HKM001LOGO ) (Read full report by clicking the link below, you may...
NEW YORK, July 2, 2012 /PRNewswire/ -- Bernstein Liebhard LLP is investigating whether the Board of Directors of Amylin Pharmaceuticals, Inc. ("Amylin" or the "Company") (NASDAQ: AMLN) breached its fiduciary duty to its shareholders in agreeing to sell Amylin to Bristol-Myers Squibb Company (NYSE: BMY). (Logo: http://photos.prnewswire.com/prnh/20120202/MM47134LOGO ) Under the terms of the agreement, Amylin shareholders will receive $31.00 in cash for each share they own. The...
NEW YORK, July 2, 2012 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against the Board of Directors of Amylin Pharmaceuticals, Inc. ("Amylin" or the "Company") (NsadaqGS: AMLN) related to the proposed acquisition of the Company by Bristol-Myers Squibb Company. The transaction is valued at approximately $5.3 billion or $31 per share. This investigation concerns whether the Board of Directors of Amylin breached their...
VANCOUVER, British Columbia, May 29, 2012 /PRNewswire-Asia/ -- Insiderslab.com has issued insider trading reports and Equity Research for the following companies: VeriFone (NYSE:PAY), Hewlett-Packard (NYSE:HPQ), eBay (NASDAQ:EBAY), Apple (NASDAQ:AAPL), J.C. Penney (NYSE:JCP), and Amylin Pharmaceuticals (NASDAQ:AMLN). (Logo: http://photos.prnewswire.com/prnh/20100419/HKM001LOGO ) (Read full report by clicking the link below, you may need to copy and paste the full link to your...
